Updates
** Shares of drugmaker Eli Lilly LLY.N fall 8.6% to $821.62
** CVS Health CVS.N says it plans to drop LLY's obesity drug Zepbound from the list of medicines it covers for reimbursement
** CVS says it would drop coverage from July 1, but keep reimbursing for rival GLP-1 weight-loss drug Wegovy after negotiating a more favorable price from Novo Nordisk NOVOb.CO
** Q1 sales of Zepbound of $2.31 billion came in slightly below analysts' estimates of $2.33 billion, as per data compiled by LSEG
** Co also cuts annual adj. profit forecast to between $20.78 per share and $22.28 per share from $22.50 per share to $24 per share previously
** Including session's moves, LLY up 7.9% YTD
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。